Quotient Sciences, a Nottingham, UK-based contract development and manufacturing organization (CDMO), has acquired Pharmaterials, a Reading, UK-based CDMO.

Quotient says it expects the acquisition to support the growth of Quotient’s Translational Pharmaceutics platform, following the acquisitions of SeaView Research, a Miami, Florida-based clinical research organization, and QS Pharma, a Charles River Laboratories CDMO unit based near Philadelphia, in February 2017.

Pharmaterials has experience in supporting the development of small-molecule drug products for oral and inhaled delivery. The company’s portfolio of services includes the characterization and optimization of drug-substance physical forms, and the development of preclinical and clinical formulations through to clinical trial manufacturing and subsequent global drug product supply. The business is located in a 48,000-square-foot facility that houses 13 GMP manufacturing suites with space for future expansion.

Source: Quotient Sciences